X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qiagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 16, 2022
Details:
Proceeds from the financing will be used to accelerate the development of Neuron23’s pipeline and expand its state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms for identifying therapeutics for devastating neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Westlake Village BioPartners
Deal Size: $33.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 16, 2020
Details:
The round will allow the company to advance two-to-three existing development candidates into the clinic in the next 24 months, and to bolster its platform to identify genetic signatures of patients most likely to respond to the development candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
